Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO William Stilley will present on September 16 at 1:30 p.m. ET, with a live webcast available. Adial focuses on addiction treatments, with its lead drug AD04 targeting Alcohol Use Disorder (AUD) via a genetic approach. A Phase 2b trial showed significant effectiveness in reducing drinking behaviors without serious safety concerns. AD04 may also help treat other addictions such as opioids and gambling.

News Market Reaction – ADIL

-1.59%

1 alert

-1.59% News Effect

On the day this news was published, ADIL declined 1.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLOTTESVILLE, VA / ACCESSWIRE / September 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

William Stilley, Chief Executive Officer of Adial Pharmaceuticals, is scheduled to present on Wednesday, September 16^th at 1:30 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in a Phase 3 clinical for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. www.adialpharma.com

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/605356/Adial-Pharmaceuticals-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference-on-September-16th

FAQ

When is Adial Pharmaceuticals presenting at the H.C. Wainwright Investment Conference?

Adial Pharmaceuticals is scheduled to present on September 16, 2020, at 1:30 p.m. Eastern Time.

What is the focus of Adial Pharmaceuticals' lead drug AD04?

AD04 is focused on treating Alcohol Use Disorder (AUD) and is being investigated for its effectiveness based on genetic profiles.

What were the results of the Phase 2b trial for AD04?

The Phase 2b trial of AD04 showed promising results, significantly reducing drinking frequency, quantity, and heavy drinking with no major safety issues.

What other disorders could AD04 potentially treat?

AD04 may also be effective in treating opioid use disorder, gambling, and obesity.

How can I access the live webcast of Adial Pharmaceuticals' presentation?

The live webcast of the presentation can be accessed on the conference event platform during the scheduled time.